THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Venture Capital Report | Life Sciences

Window of opportunity

Momenta was able to launch an IPO in 2004

By Robert Weisman
Globe Staff / November 8, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

CAMBRIDGE -- Three-year-old Momenta Pharmaceuticals Inc. already has seen its share of milestones. Its scientists cloned the first Heparin sugar-degrading enzyme, a breakthrough in understanding the role of complex sugars as a conduit for viruses and diseases. Its executives recruited medical luminaries like M. Judah Folkman and Eugene Braunwald to the company's scientific advisory board. (Full article: 1045 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass